{"id":30200,"date":"2026-03-11T21:25:13","date_gmt":"2026-03-11T21:25:13","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/30200\/"},"modified":"2026-03-11T21:25:13","modified_gmt":"2026-03-11T21:25:13","slug":"whats-going-on-with-olema-pharmaceuticals-stock-on-wednesday-olema-pharmaceuticals-nasdaqolma","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/30200\/","title":{"rendered":"What’s Going On With Olema Pharmaceuticals Stock On Wednesday? – Olema Pharmaceuticals (NASDAQ:OLMA)"},"content":{"rendered":"

Olema Pharmaceuticals Inc. (NASDAQ:<\/a>OLMA<\/a>) stock plunged on Monday as the company<\/a> navigates recent developments in its clinical trials.<\/p>\n

On Monday, Roche Holdings AG (OTC:<\/a>RHHBY<\/a>) released data from the phase 3 persevERA Breast Cancer study of giredestrant combined with palbociclib in advanced cancer patients.<\/p>\n

The study did not meet its primary<\/a> objective of a statistically significant improvement in progression-free survival versus letrozole plus palbociclib.<\/p>\n

The study showed a numerical improvement.<\/p>\n

Roche\u2019s Giredestrant is an investigational, oral, potent next-generation selective oestrogen receptor degrader (SERD) and full antagonist.<\/p>\n

Olema Pharmaceuticals\u2018 Palazestrant Clinical Trial Update<\/p>\n

Olema’s lead product candidate, Palazestrant, is a novel, orally available complete estrogen receptor antagonist (CERAN) and SERD.<\/p>\n

The stock is experiencing bullish momentum following updates on its lead product candidate, Palazestrant, which is undergoing various clinical trials for breast cancer.<\/p>\n

In November 2025, Olema Pharmaceuticals surged over 200% after Roche released phase 3 results from the lidERA Breast Cancer study of giredestrant in early-stage breast cancer<\/a>.<\/p>\n

OLMA\u2019s Bearish Technical Indicators<\/p>\n

The stock is currently trading 26.2% below its 20-day SMA and 19% below its 100-day SMA, indicating a bearish trend in the short to medium term. <\/p>\n

Shares have increased by 294.05% over the past 12 months and are currently positioned closer to their 52-week lows than highs.<\/p>\n

The RSI is at 34.36, which is considered neutral territory, while the MACD is at -0.6379, below its signal line, indicating bearish pressure on the stock. <\/p>\n

The combination of neutral RSI and bearish MACD suggests mixed momentum, reflecting uncertainty in the stock’s near-term outlook.<\/p>\n

Key Resistance: $22.50<\/p>\n

Key Support: $13.50
\nOLMA\u2019s Premarket Price Movement<\/p>\n

OLMA Price Action: Olema Pharmaceuticals shares were down 2.54% at $15.36 at the time of publication on Wednesday, according to Benzinga Pro data<\/a>.<\/p>\n

Image via Shutterstock<\/p>\n

Market News and Data brought to you by Benzinga APIs<\/a><\/p>\n

\u00a9 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.<\/p>\n

To add Benzinga News as your preferred source on Google, click here<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"Olema Pharmaceuticals Inc. (NASDAQ:OLMA) stock plunged on Monday as the company navigates recent developments in its clinical trials.…\n","protected":false},"author":2,"featured_media":30201,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[124],"tags":[342,1016,344,346,343,345,341,340,134,7044,347,18278,1335],"class_list":{"0":"post-30200","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-roche","8":"tag-category-biotech","9":"tag-category-general","10":"tag-category-health-care","11":"tag-category-movers","12":"tag-category-news","13":"tag-category-top-stories","14":"tag-cms-wordpress","15":"tag-pageisbzpro-bz","16":"tag-roche","17":"tag-symbol-olma","18":"tag-symbol-rhhby","19":"tag-tag-benzai","20":"tag-tag-why-its-moving"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116212657277817074","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/30200","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=30200"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/30200\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/30201"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=30200"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=30200"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=30200"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}